Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs MannKind Corporation

SG&A Expenses: Blueprint vs. MannKind - A Decade of Change

__timestampBlueprint Medicines CorporationMannKind Corporation
Wednesday, January 1, 2014789000079383000
Thursday, January 1, 201514456000108402000
Friday, January 1, 20161921800046928000
Sunday, January 1, 20172798600074959000
Monday, January 1, 20184792800079716000
Tuesday, January 1, 20199638800074669000
Wednesday, January 1, 202015774300059040000
Friday, January 1, 202119529300077417000
Saturday, January 1, 202223737400091473000
Sunday, January 1, 202329514100094314000
Monday, January 1, 2024359272000
Loading chart...

Infusing magic into the data realm

A Tale of Two Companies: SG&A Expenses Over Time

In the competitive landscape of biotechnology, understanding the financial strategies of companies is crucial. Blueprint Medicines Corporation and MannKind Corporation, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Blueprint Medicines has seen a staggering increase of over 3,600% in SG&A expenses, starting from a modest $7.89 million in 2014 to nearly $295 million in 2023. This growth reflects their aggressive expansion and investment in administrative capabilities. In contrast, MannKind Corporation's SG&A expenses have remained relatively stable, with a slight increase of about 19% over the same period, peaking at approximately $108 million in 2015. This stability suggests a more conservative financial approach. These trends highlight the diverse strategies within the biotech sector, offering insights into how companies allocate resources to drive growth and maintain competitiveness.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025